Advertisement

Stem cell trial nearly a go?

The first clinical trial treatment based on embryonic stem cells may soon get the go ahead. In May, the Food and Drug Administration linkurl:placed a hold;http://www.the-scientist.com/blog/display/54647/ on a clinical trial application submitted by Geron Corporation, a California-based biotech. The company submitted a 22,500-page Investigational New Drug application to the FDA for an embryonic stem cell-derived compound -- called GRNOPC1 -- to treat spinal cord injury. Geron president and CEO

By | October 17, 2008

The first clinical trial treatment based on embryonic stem cells may soon get the go ahead. In May, the Food and Drug Administration linkurl:placed a hold;http://www.the-scientist.com/blog/display/54647/ on a clinical trial application submitted by Geron Corporation, a California-based biotech. The company submitted a 22,500-page Investigational New Drug application to the FDA for an embryonic stem cell-derived compound -- called GRNOPC1 -- to treat spinal cord injury. Geron president and CEO, Tom Okarma, said at the New York Stem Cell Foundation conference at Rockefeller University on Wednesday (October 15) that the company has had to "educate" the FDA on all the procedures used to grow, quantify, and characterize their stem cell populations. He added that there is no evidence of political pressures behind the hold, and he thinks the FDA did the right thing to hold the trial, in order to get a grasp on the science and ensure safety. But the FDA is nearing the end of its linkurl:review process;http://www.the-scientist.com/blog/display/54544/ and may lift the hold and allow clinical trials to commence within the next three months, Okarma told The Scientist. "We've got our arms wrapped around it," he added. "It's been a long education process."
Advertisement
Advertisement

Popular Now

  1. How Fats Influence the Microbiome
  2. Censored Professor Quits
    The Nutshell Censored Professor Quits

    Alice Dreger is resigning from the faculty of Northwestern University, claiming that the administration censored her work in a faculty journal.

  3. Mitochondria Exchange
    News Analysis Mitochondria Exchange

    A decade of research on intercellular mitochondrial transfer has answered some long-standing questions and raised new ones.

  4. Opinion: Engineering the Epigenome
Advertisement
ProteinSimple
ProteinSimple
Advertisement